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Abstract Anandamide (ANA), an endogenous cannabinoid, can
be generated by activated macrophages during endotoxin shock
and is thought to be a paracrine contributor to hypotension. We
discovered that ANA in saline/ethanol solution and in serum was
efficiently adsorbed in a polymyxin B (PMB)-immobilized beads
column and eluted with ethanol. We confirmed the direct binding
of PMB to ANA by using surface plasmon resonance. The
adsorption of ANA by PMB may abolish the diverse effects of
ANA such as hypotension, immunosuppression, and cytotoxicity,
and may suggest a new therapeutic strategy for endotoxin shock.
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1. Introduction
Since lipopolysaccharide (LPS) shock is still a serious event
with high mortality and multiple organ failure, the develop-
ment of e⁄cient treatments has been expected. Such media-
tors as tumor necrosis factor-K (TNF-K), interleukin-1 (IL-1),
platelet activating factor, thromboxane A2, and NO from in-
ducible NO synthase have been proposed as candidate medi-
ators of LPS shock. However, pharmacological antagonists,
inhibitors, and monoclonal antibodies of these factors have
never shown a su⁄cient e¡ect on LPS shock [1,2], therefore,
the existence of the other mediators has been proposed. Re-
cently it was described that anandamide (ANA) is generated
by macrophages in response to LPS during Gram-negative
bacterial sepsis, and endogenous cannabinoids may have an
important role in the pathomechanism of LPS shock, espe-
cially hypotension [3].
ANA as an endogenous cannabinoid was initially isolated
from porcine brain, and shown to exert its diverse biological
functions through cannabinoid receptors, CB1 and CB2 [4].
Thereafter it was found to exist not only in the brain but also
in various peripheral tissues [5]. Functional studies have dem-
onstrated that it may possess similar functions to cannabinoid
in the brain and immune system [6^8]. It has been reported
that a cannabinoid, v9-tetrahydrocannabinol (THC), may reg-
ulate immune cells in a biphasic manner. Lower concentra-
tions of THC enhanced production and release of proin£am-
matory cytokines including IL-1, IL-6, TNF-K, and NO, but
higher concentrations suppressed the e¡ects of the above-men-
tioned molecules [9,10]. ANA may also play a similar role in
immune cells to THC. Recent evidence indicates that activa-
tion of vascular cannabinoid receptors contributes to hypo-
tension caused by hemorrhagic or endotoxic shock, and that
ANA and 2-arachidonoylglycerol (2-AG) probably serve as
paracrine mediators of hypotension via activation of the
CB1 receptor expressed in the peripheral vasculature [11^14].
Polymyxin B (PMB), which is formed from a cyclic hepta-
peptide moiety linked to a peptide side chain which terminates
with a short fatty acid residue, blocks the biological e¡ects of
LPS through binding to LPS [15]. However, the potent toxic
e¡ect of PMB to mammalian cells limits its clinical use. To
reduce this toxic e¡ect and derive bene¢t from the LPS block-
ing property, PMB was immobilized onto insoluble ¢bers cre-
ating a hemoperfusion column to use as an extracorporeal
endotoxin removal device for the treatment of patients with
Gram-negative bacterial sepsis. Hemoperfusion using this de-
vice improves hypotension and results in an increment of sur-
vival rates in both experimental animal models and patients
with LPS shock [16^19]. This led us to determine whether
PMB binds to ANA resulting in the neutralization of the
biological function of ANA.
In the present study, we show that PMB directly binds to
ANA and neutralizes its biological activity. These observa-
tions may present a new strategy for the treatment of endo-
toxin-induced hypotension.
2. Materials and methods
2.1. Materials
ANA, LPS (Escherichia coli strain 055:B5), phosphatidylcholine
(PC) and arachidonic acid (AA) were obtained from Sigma Chemical
Co. (St. Louis, MO, USA). 2-AG was obtained from Calbiochem-
Novabiochem Co. (La Jolla, CA, USA). PMB sulfate was obtained
from Wako Pure Chemical Co. (Osaka, Japan), and A⁄-Prep poly-
myxin matrix from Bio-Rad Laboratories (Hercules, CA, USA). An-
hydrate benzene, acetonitrile and water were of HPLC grade. All
other reagents used were of analytical grade. Stock solution of anan-
damide was prepared in ethanol (EtOH) and stored in aliquots at
380‡C.
2.2. Cell culture and cell viability test
Rat pheochromocytoma (PC-12) cells were grown as described pre-
viously [20] in RPMI 1640 medium, supplemented with 10% heat-
inactivated (at 56‡C for 30 min) horse serum, and 5% fetal bovine
serum, 100 Wg/ml penicillin, and 100 Wg/ml streptomycin under 5%
CO2 and 100% humidity at 37‡C. Cell viability (cytotoxicity) was
assayed by £uorescence-activated cell sorting (FACS) analyzer (EP-
ICS, Coulter, USA) using propidium iodide (PI), as described previ-
ously [21]. Brie£y, PC-12 cells were plated at a density of 2.5U105
cells per 35 mm dish. Following 18 h culture, monolayers were washed
with serum-free RPMI medium once, and pretreated with the indi-
cated concentrations of PMB, and the monolayers were incubated
with or without 10 WM ANA for 24 h in RPMI medium without
serum. Then the harvested cells were washed with PBS, and centri-
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fuged (200Ug for 5 min). The pellet was resuspended in 70% ethanol
(2 ml), and incubated at 320‡C for 20 min. Following an additional
15 min of incubation with PI (5 Wg/ml of PBS solution) in the dark in
the presence of RNase (5 Wg/ml), cell viability was tested (2U104 cells
each time) using a FACS analyzer.
2.3. PMB-immobilized beads a⁄nity chromatography
A chromatography column (0.5U3 cm), which was packed with
500 Wl of 50% A⁄-Prep PMB suspension, was washed with 1 ml of
saline and centrifuged to remove the saline. Then the various amounts
of ANA dissolved in 100 Wl of 50% saline/ethanol were loaded on the
columns and the e¥uents were collected. The columns were washed
with 500 Wl of saline and the washing solution was collected. The
ANA adsorbed on the beads was eluted by 200 Wl of 95% ethanol.
ANA in all solutions was assayed using reverse phase high perform-
ance liquid chromatography (RP-HPLC). In the experiment of verify-
ing the capacity of PMB-immobilized beads to adsorb ANA in the
presence of human serum, various amounts of ANA dissolved in 1 ml
solutions with increasing concentrations of human serum were loaded
onto the column packed with PMB-immobilized beads. After inten-
sive washing with saline, ANA adsorbed on the beads was eluted with
200 Wl of 95% ethanol and the total contents in the collected eluates
were determined by RP-HPLC.
2.4. HPLC analysis
HPLC was performed as described by Lang et al. [22]. Brie£y, a
Gilson System (Gilson Inc., USA) equipped with a 305 pump and a
118 UV-Vis detector was used and separation was carried out on a
TSK gel ODS 80TM (50U4.6 mm, i.d. 5 Wm) column (Tosoh, Tokyo,
Japan) with acetonitrile and 8.5% aqueous phosphoric acid (9:1, v/v)
at a £ow rate of 1 ml/min. Quantitation was based on the integration
of peak areas at 204 nm. The amount of product formed was calcu-
lated from calibration curves of appropriate standards.
2.5. Surface plasmon resonance (SPR) analysis
SPR analysis was performed using a BIAcore 2000 biosensor sys-
tem (Pharmacia Biosensor AB, Uppsala, Sweden). All experiments
were performed at 20‡C with a constant £ow rate of 10 Wl/min.
PMB was covalently immobilized directly on a carboxymethylated
dextran matrix (CM5 sensor chips, Pharmacia Biosensor) at a con-
centration of 40 mg/ml in 10 mM sodium acetate, pH 4.8. PMB was
coupled through its amino group according to the amine coupling kit
supplied by the manufacturer. Nearly 3000 resonance units (RU) of
PMB were immobilized under these conditions, where 1 RU corre-
sponds to an immobilized PMB concentration of V1 pg/mm2. The
unreacted moieties on the surface were blocked with 35 Wl of 1 mM
ethanolamine pH 8.5. The immobilization of PMB was carried out in
10 mM HEPES, pH 7.4, 150 mM NaCl and 3.4 mM EDTA. Inter-
action of ANA and PMB was carried out as follows: the sensor chip
(CM5) with immobilized PMB was brought into contact with saline
containing 4% ethanol bu¡er. The £ow rate of the bu¡er solution was
kept at a high level (10 Wl/min) in order to prevent mass transport
limitations at the sensor surface/solution interface. After a stable base-
line was obtained, 30 Wl ANA or saline containing ethanol was in-
jected through the PMB surface. Next, 40 Wl saline containing 4%
ethanol bu¡er was injected to observe the dissociation.
3. Results
3.1. PMB neutralizes the cytotoxic e¡ect of ANA
ANA at a dose of 10 WM induced the death of PC-12 cells
cultured in serum-free medium (Fig. 1). Treatment of the cells
with PMB prevented cell death induced by ANA in a dose-
dependent manner, as compared to the vehicle (0.01% etha-
nol), because ANA was dissolved in ethanol. This result sug-
gests that PMB adsorbs ANA and neutralizes or inhibits the
biological function of ANA.
3.2. PMB directly binds to ANA
To elucidate the mechanism of the inactivation of the cyto-
toxic e¡ect of ANA on PC-12 cells in culture, we investigated
the interaction of PMB and ANA in vitro using PMB-immo-
bilized beads. ANA was dissolved in saline containing 50%
ethanol and loaded onto a column packed with PMB-immo-
bilized beads. The contents of the feed (before column), e¥u-
ent (after column), and eluates of saline and 95% ethanol,
respectively, were determined by RP-HPLC. The chromato-
grams of ANA in each case mentioned above are shown in
Fig. 2. In our analytic system, the retention time for standard
ANA is 4.77 min. Before passing through the PMB-immobi-
lized beads, ANA appeared as a high and sharp peak at
4.77 min, but after £owing through the column, the 4.77 min
peak disappeared in both the e¥uent and eluate of saline. A
large amount of saline failed to elute ANA from the column,
whereas 95% ethanol eluted almost all ANA from the column
(Fig. 2, eluate of 95% ethanol). Recovery of ANA in the
eluate of 95% ethanol was as high as 95%. These results dem-
onstrated that PMB-immobilized beads strongly adsorbed
ANA.
3.3. Capacity of PMB-immobilized beads to adsorb ANA
To verify the speci¢city and capacity of ANA binding to
PMB-immobilized beads, we investigated the binding study
using increasing amounts of ANA as shown in Table 1. Dif-
ferent amounts of ANA in 100 Wl of a 1:1 ethanol/saline so-
lution were loaded on a column packed with 500 Wl of a 50%
suspension of A⁄-Prep polymyxin support. The content of
ANA in the e¥uent of each concentration was determined
Table 1
Capacity of PMB-immobilized beads to adsorb ANA, AA and 2-AG
Loaded substance (Wg) Recovery (%)
e¥uent saline 50% ethanol 70% ethanol 95% ethanol
ANA
5 0 0 0 47.1 þ 5.1 91.5 þ 3.2
25 0 0 0.77 þ 0.23 53.3 þ 4.3 93.4 þ 2.7
50 0 0 4.30 þ 0.68 61.2 þ 3.8 94.2 þ 2.1
100 0.89 0.2 10.9 þ 1.5 70.4 þ 3.5 94.6 þ 2.3
300 67 ^ ^ ^ ^
AA
100 4.3 1.5 26.5 þ 4.7 82.1 þ 4.7 95.4 þ 3.2
2-AG
100 0.21 0 8.2 þ 1.1 65.3 þ 1.8 93.8 þ 2.6
Various amounts of ANA, 100 Wg of AA or 100 Wg of 2-AG in 100 Wl of 1:1 ethanol/saline were loaded on a column packed with 500 Wl of
suspension of PMB-immobilized beads. The ANA amount in the e¥uent, eluate of 1.5 ml saline and eluate of 200 Wl ethanol at indicated con-
centrations was determined by RP-HPLC. The recovery of ANA in e¥uent and each eluate is represented as a percentage relative to the
amount of ANA prior to loading.
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by RP-HPLC. Only 0.89% of total ANA was detected in the
e¥uent of 100 Wg/ml ANA, while 67% of total ANA corre-
sponding to 300 Wg of ANA passed through the column of
PMB-immobilized beads, indicating that about 100 Wg of
ANA was adsorbed by the PMB-immobilized beads (Table
1). Thus, the capacity of PMB-immobilized beads to adsorb
ANA is calculated to be about 0.4 mg/ml of PMB beads
suspension. As shown in Table 1, although a high concentra-
tion of ANA was loaded, saline failed to elute ANA from the
column. 50% ethanol was unable to elute ANA from the
column until the amount of loaded ANA exceeded 25 Wg,
and even when 100 Wg of ANA was loaded, only 10.9% of
ANA adsorbed in the column was eluted by 50% ethanol. In
contrast, 75% ethanol and 95% ethanol recovered ANA at a
high e⁄ciency, especially 95% ethanol, which eluted more
than 91% of ANA from the PMB beads at all concentrations
of ANA loaded. Generally, with an increase in the concen-
tration of ethanol, the capacity of ethanol to elute ANA from
the column was increased, and only a high concentration of
ethanol was capable of eluting ANA completely. PMB also
adsorbed 2-AG and AA. Using the same concentrations as
ANA, the adsorptive capacity of PMB for 2-AG seemed to
be greater, but that for AA lower than for ANA.
3.4. PMB adsorbs ANA in the presence of serum
It is known that the binding of LPS to PMB is markedly
reduced because of the presence of LPS binding protein in the
serum. It has also been reported that speci¢c transporter of
ANA is present on the surface of human astrocytoma cell
lines [23]. Thus, to elucidate whether the molecule that binds
to ANA is present in the serum, we examined the capacity of
PMB-immobilized beads in the column to adsorb ANA in the
presence of the increasing amounts of human serum (0, 20, 40,
80, and 100% of serum). Addition of the serum to the solution
containing di¡erent concentrations of ANA (50, 100, 200,
500, and 1000 ng/ml) gave rise to a decreased adsorption of
ANA by PMB beads. However, the e¡ect of serum was not
saturable, even at the maximum concentration (100%) of
Fig. 1. PMB prevents ANA-induced PC-12 cell death. PC-12 cells
were plated onto a 6 well dish at a density of 2U105 cells/well. Fol-
lowing 18 h culture, cells were pretreated with PMB for 1 h, then
incubated with 10 WM of ANA or 0.01% ethanol (EtOH, as a ve-
hicle) for an additional 24 h in serum-free medium. The cell viabil-
ity was determined as described in Section 2. The results are
means þ S.D. of three independent experiments.
Fig. 2. RP-HPLC pro¢les showing the adsorption of ANA by
PMB-immobilized beads. 10 Wg of standard ANA was dissolved in
100 Wl of 1:1 ethanol/saline and loaded on a column packed with
500 Wl of PMB bead suspension. The content of ANA in the load-
ing solution (before column), e¥uent (after column), eluate of 1.5 ml
saline, and eluate of 200 Wl of 95% ethanol was analyzed by RP-
HPLC. The results were from ¢ve separate analyses. The recovery
of ANA in the eluate of 95% ethanol is more than 95% with respect
to the amount prior to loading.
Fig. 3. Overlay plot of sensorgrams depicting the interaction of
ANA with immobilized PMB. A: Interaction of PMB with ANA.
ANA in a concentration range of 5.76^57.6 WM was injected for
250 s at a £ow rate of 10 Wl/min. The concentration of ANA from
the bottom to the top is 5.76, 11.5, 29.8 and 57.6 WM. Following
250 s injection, the bu¡er was passed over the chip at the same £ow
rate as above. B: Interaction of PMB with AA, LPS and PC. AA,
LPS and PC at the same concentration of 29.8 WM were injected
for 250 s at a £ow rate of 10 Wl/min. The sensorgrams show their
binding to PMB.
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serum containing each mentioned concentration of ANA.
Moreover, the decrement rate of ANA adsorption by PMB
beads was linear and serum concentration-dependent. Never-
theless, about 75% of 1000 ng/ml of ANA was recovered at
the maximum concentration (100%) of serum (data not
shown). Thus, we supposed that there are no molecules that
can speci¢cally bind to ANA. However, more investigations
are required to draw a ¢nal conclusion at this point. The
speci¢c and strong binding capacity of PMB to ANA in the
presence of serum may introduce a new method to determine
ANA in the serum or other £uids.
3.5. Con¢rmation of ANA binding to PMB by SPR
Further con¢rmation of binding of PMB to ANA and its
molecular interaction was sought by SPR. PMB was cova-
lently immobilized onto carboxymethylated dextran matrix
covered on the sensor chip. During a 60 min interval when
the sensor was in contact with the PMB solution, an increase
in RU was observed, which indicated binding of PMB to the
surface. Nearly 3000 RU of PMB was immobilized under
these conditions. A typical sensorgram for the binding of
the varying concentrations of ANA with PMB immobilized
on the CM5 sensor chip is shown in Fig. 3A. The rapid in-
crease of RU by binding of ANA to PMB with time re£ects
the associated changes in mass during the reaction, demon-
strating the direct interaction between PMB and ANA. This
interaction can also be observed between PMB and AA as
shown in Fig. 3B. An immediate increase in mass was ob-
served when a solution of AA was passed over the sensor
chips to which PMB was bound (Fig. 3B, curve a). As a
positive control, direct binding of LPS to the PMB sensor
chip surface was also observed (Fig. 3B, curve b). However,
this selective binding was not observed when a solution of PC
was passed over the sensor chip containing PMB (Fig. 3B,
curve c).
4. Discussion
PMB is formed from a cyclic heptapeptide moiety and a
peptide side chain that terminates with a short fatty acid res-
idue. It is known that PMB can inhibit biological e¡ects of
LPS through its high-a⁄nity binding to lipid A, the biolog-
ically active moiety of LPS [15]. However, the molecular
mechanism and manner of binding are still under debate
[24^26].
ANA is composed of a highly hydrophobic cis-tetraene C20
chain, a polar carboxamide group and a hydroxyethyl head
group [1,27]. Unlike LPS, ANA has only a long N,O-acyl
chain and a hydroxy group, and does not contain any ionic
group within the molecule. Hence, the interaction between
ANA and PMB is probably driven primarily by hydrophobic
force. Based on this deduction, the PMB-immobilized beads
adsorbed ANA from 1:1 ethanol/saline or full serum probably
by hydrophobic force. The hydrophobic force between PMB
and ANA is so strong that saline and low concentrations of
ethanol did not elute ANA from PMB-immobilized beads;
only high concentrations of ethanol did. SPR, a rapid method
for evaluating the elementary interaction between a molecule
and its complementary ligand [28^30], reinforced the ¢nding
that PMB adsorbed ANA (Fig. 3A). In the sensorgram of
ANA, a much higher RU can be seen than that in LPS, in-
dicating that more ANA was adsorbed on the PMB-immobi-
lized sensor chip. Some of the ANA adsorbed on the PMB-
immobilized chip was dissociated by 4% ethanol/saline solu-
tion but LPS adsorbed on the same chip was not (Fig. 3A,B).
However, neither 4% ethanol/saline solution nor 50% ethanol/
saline was able to dissociate all ANA adsorbed on the PMB-
immobilized chip, so the sensorgram curve of ANA cannot
return to baseline following washing with the ethanol/saline
solution above. In contrast, 50% ethanol/saline failed to elute
ANA from PMB-immobilized beads. The high recovery of
ANA after washing the column with a large amount of 50%
ethanol/saline indicated that a strong adsorption occurred be-
tween ANA and PMB. The di¡erence may be due to the
possibility that a large amount of PMB was covalently linked
to beads, and the stereoscopic conformation of PMB formed
by each carrier facilitated PMB adsorption of ANA both in
larger amounts and at a stronger force than PMB on the SPR
sensor chip.
To elucidate which moiety in the ANA molecule plays the
main role in the adsorption process of ANA by PMB, we
investigated whether other lipids such as AA, 2-AG and PC
are adsorbed to PMB. PMB-immobilized beads adsorbed AA
and 2-AG as measured by RP-HPLC (Table 1), but not PC,
which was detected by thin layer chromatography (data not
shown). Since the same structure of the hydrophobic cis-tet-
raene C20 chain is shared by ANA, AA and 2-AG, but not by
PC (Fig. 4), the conformation of the cis-tetraene C20 chain
may probably match the conformation of PMB and lead the
interaction of ANA with PMB by hydrophobic force. The fact
that there was no signi¢cant di¡erence in the adsorptive ca-
pacity of these lipids by PMB indicated that the electrostatic
interaction is probably a minor contributor to the interaction
with PMB (Table 1). Like the sensorgram of ANA, the high
RU in the AA sensorgram declined after washing with the 4%
ethanol/saline bu¡er. However, washing with 4% ethanol/sa-
line or even with 50% ethanol/saline did not elute all AA
absorbed on the PMB-immobilized sensor chip, since the sen-
sorgram curve of AA did not decline to the baseline by wash-
ing with these ethanol/saline bu¡ers (Fig. 3B). PC does not
contain the cis-tetraene C20 chain in its molecule, so it shows
no interaction with PMB, as previously reported [31,32]. One
thing must be explained. Since ANA, AA, and PC were dis-
solved in a solution that is di¡erent from the running bu¡er,
Fig. 4. Chemical structures of ANA, AA and 2-AG.
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there were a sharp increase and an equally sharp decrease in
RU at the time when the loading bu¡er and running bu¡er
were switched, respectively.
Several studies have demonstrated that ANA and 2-AG
could elicit CB1 receptor-mediated hypotension in rats [11^
14]. The endogenous ANA was identi¢ed in LPS-activated
macrophages in vitro, and was thought to be a paracrine
mediator of LPS-induced hypotension via the activation of
the vascular CB1 receptor, because hypotension is prevented
by pretreatment of LPS-recipient rats with the CB1 receptor
antagonist SR141716A. When endotoxic shock patients are
treated with a PMB-immobilized ¢ber hemoperfusion column,
which is generally applied for removing endotoxin, the hypo-
tension is improved signi¢cantly, however, the mechanism of
this anti-hypotensive e¡ect remains unknown [18,19]. Suppos-
ing that endogenously generated ANA by the LPS stimulation
could be adsorbed with a PMB-immobilized hemoperfusion
column, we examined the columns which were used for pa-
tients with LPS shock and could detect that a large amount of
ANA was adsorbed onto the column (data not shown). There-
fore, the removal of endogenous ANA from the circulation of
shock patients by the adsorption of a PMB-immobilized he-
moperfusion column may contribute to the improvement of
endotoxin-induced hypotension.
It has been reported that THC induces neuronal cell death
under serum-free culture conditions [33]. We found that ANA
was able to induce PC-12 cell death under the same culture
conditions as THC. However, the cell death induced by ANA
was prevented by pretreatment with PMB. This result indi-
cates that PMB adsorbs ANA and neutralizes the cytotoxic
function of ANA.
In conclusion, we ¢rst found that PMB adsorbed ANA,
which is signi¢cant in elucidation of the mechanism of septic
shock-induced hypotension, and extends the application of
PMB-immobilized beads or membranes in clinical treatment
of endotoxin-induced shock and analysis of ANA.
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